Lilly cuts Zepbound vial prices and adds 7.5 mg and 10 mg with a 45-day refill condition

Eli Lilly said on Feb. 25, 2025, that it is adding 7.5 mg and 10 mg single-dose vials of Zepbound (tirzepatide) to its cash-pay lineup and cutting the price of the two lower-dose vials it already sold ^[3][5]. The new higher-dose vials cost $499 a month — but only under a new "Zepbound Self Pay Journey Program" that requires a first fill or a refill within 45 days of the prior delivery ^[3].

What changed

Under the update, the 2.5 mg vial now costs $349 a month and the 5 mg vial $499 a month ^[3][5]. Reuters reported those are each roughly $50 less than what Lilly had been charging for a month's supply of those doses ^[4].

The 7.5 mg and 10 mg vials are new to the program. Their stated prices are $599 and $699 per month, reduced to $499 per month "at first fill and refills that occur within 45 days of prior delivery" ^[3][5]. That timing condition is the first of its kind in Lilly's self-pay vial program. If a refill falls outside the 45-day window, the press release indicates the higher $599 or $699 price applies ^[3].

All of these vials are sold only through LillyDirect Self Pay Pharmacy Solutions, Lilly's direct-to-consumer channel, which the company says removes "third-party supply chain entities" so patients can buy outside of insurance ^[3][5]. Lilly first began selling vials of the two lowest Zepbound doses in August 2024; the drug is more commonly sold in single-dose pens ^[4]. Patrik Jonsson, president of Lilly Cardiometabolic Health and Lilly USA, told Reuters that more than 10% of patients starting Zepbound have begun on vials since that launch ^[4].

For comparison, Reuters noted the $499 price is nearly 23% less than the $650 Lilly charges for autoinjector pens sold to patients who have insurance but no coverage for the medicine ^[4]. It is still more than the $231 to $330 that compounding pharmacies charged on average for copies of tirzepatide and semaglutide ^[4].

The timing matters. The FDA removed Zepbound from its shortage list in December 2024 and removed Wegovy (semaglutide) on Feb. 21, 2025, telling compounders to stop selling copies in the coming months ^[4]. Compounders, led by the Outsourcing Facilities Association, sued the FDA on Feb. 24 over the semaglutide decision ^[4]. Bernstein analyst Courtney Breen said Lilly's expanded vial offering "is sure to act as a sweetener for those that are having their compounded supply come to an end" ^[4].

Why it matters for patients

The practical change for cash-paying patients is twofold: more doses are now available in the cheaper vial format, and the price for the two new higher doses depends on refill timing rather than being a flat monthly rate.

The 45-day condition ties the price to the calendar. A gap caused by a pause in treatment, a delayed shipment, a dose change, or simply waiting to reorder could mean paying $599 or $699 instead of $499 for those strengths ^[3][5]. The sources do not spell out how Lilly handles exceptions, whether the clock runs from the delivery date or the order date in every case, or what happens if a shipment is delayed by the pharmacy — those details are not yet known from the announcement.

Also worth noting: Zepbound's approved strengths go up to 15 mg, and the recommended maintenance dosages are 5 mg, 10 mg or 15 mg once weekly ^[3]. The self-pay vial program covers 2.5 mg, 5 mg, 7.5 mg and 10 mg only ^[3][5], so the 12.5 mg and 15 mg strengths remain available in pens rather than in this discounted vial channel.

Lilly framed the move as a response to coverage gaps. "Every major medical organization and establishment recognizes obesity as a chronic disease, yet insurance and federal programs do not systematically cover people living with obesity for medical care," Jonsson said ^[3][5]. Joe Nadglowski of the Obesity Action Coalition called it "another step forward" but added that "we still have a long way to go" on coverage ^[3][5].

What happens next

Competing cash-pay offers followed. By May 1, 2025, Novo Nordisk was selling Wegovy directly for $499 a month and had struck a deal making it the preferred obesity GLP-1 on CVS Caremark's largest commercial formularies starting July 1, a change that excludes Zepbound from those standard lists ^[2].